Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuo Takimoto

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 6, 2004
[Chronic myelogenous leukemia following therapy for pineal germinoma]Masaaki Noda, Tomoko Shoda, Yasuo Takimoto, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|July 30, 2003
[Single-agent thalidomide for advanced and refractory multiple myeloma]Yoshiko Okikawa, Yasuo Takimoto, Masaaki Noda, et al.
International Journal of Hematology|June 29, 2004
Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cellsYoshiko Okikawa, Akira Sakai, Yasuo Takimoto, et al.
Psychiatry and Clinical Neurosciences|September 19, 2007
Sitting balance as an early predictor of functional improvement in association with depressive symptoms in stroke patientsSeiji Hama, Hidehisa Yamashita, Masaya Shigenobu, et al.
British Journal of Haematology|February 14, 2002
High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphomaKen Kuramoto, Akira Sakai, Kazushi Shigemasa, et al.
International Journal of Hematology|May 26, 2005
The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agentsYoshiaki Kuroda, Akira Sakai, Yoshiko Okikawa, et al.
British Journal of Haematology|January 25, 2003
A possible role for the loss of CD27-CD70 interaction in myelomagenesisYuta Katayama, Akira Sakai, Naohide Oue, et al.
International Journal of Oncology|August 4, 2004
Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cellsYuta Katayama, Akira Sakai, Yoshiko Okikawa, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 6, 2004
[Chronic myelogenous leukemia following therapy for pineal germinoma]Masaaki Noda, Tomoko Shoda, Yasuo Takimoto, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|July 30, 2003
[Single-agent thalidomide for advanced and refractory multiple myeloma]Yoshiko Okikawa, Yasuo Takimoto, Masaaki Noda, et al.
International Journal of Hematology|June 29, 2004
Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cellsYoshiko Okikawa, Akira Sakai, Yasuo Takimoto, et al.
Psychiatry and Clinical Neurosciences|September 19, 2007
Sitting balance as an early predictor of functional improvement in association with depressive symptoms in stroke patientsSeiji Hama, Hidehisa Yamashita, Masaya Shigenobu, et al.
British Journal of Haematology|February 14, 2002
High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphomaKen Kuramoto, Akira Sakai, Kazushi Shigemasa, et al.
International Journal of Hematology|May 26, 2005
The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agentsYoshiaki Kuroda, Akira Sakai, Yoshiko Okikawa, et al.
British Journal of Haematology|January 25, 2003
A possible role for the loss of CD27-CD70 interaction in myelomagenesisYuta Katayama, Akira Sakai, Naohide Oue, et al.
International Journal of Oncology|August 4, 2004
Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cellsYuta Katayama, Akira Sakai, Yoshiko Okikawa, et al.
Pageof 1